FINWIRES · TerminalLIVE
FINWIRES

Telix Pharmaceuticals' Investigational Imaging Agent May Potentially Diagnose a Range of Kidney Cancers

By

Telix Pharmaceuticals' (ASX:TLX) investigational imaging agent TLX250-Px has the potential to help diagnose kidney cancers beyond just clear cell renal cell carcinoma, or ccRCC, the company said Tuesday, citing an independent analysis published in the European Urology scientific journal.

The analysis of phase three trial data showed that positive PET scan findings were "highly predictive" of malignancy overall, including in non-clear cell renal cell carcinoma, with a reported positive predictive value of 98%, the company said.

"Essentially all false-positives for ccRCC in the ZIRCON study have now been shown to be other malignant kidney cancer subtypes, reducing the risk of overtreatment and further supporting clinical adoption," said Telix Group Chief Medical Officer David Cade.

Related Articles

Asia

Atul Auto's Sales Rise 74% in April

Three-wheeler manufacturer Atul Auto's (NSE:ATULAUTO, BOM:531795) total sales jumped 74% to 3,001 units in April from 1,725 units sold a year ago, according to a Friday filing to the Indian stock exchanges.Of the total, domestic sales grew sharply year-on-year to 2,478 units in April from 1,427 units.

BOM:531795NSE:ATULAUTO
Asia

Leader Education's Fiscal H1 Profit Falls 17%

Leader Education (HKG:1449) booked 20.2 million yuan in attributable profit for the fiscal first half ended Feb. 28, down 17% from 24.2 million yuan a year earlier, according to a Hong Kong bourse filing Sunday.The higher education services company's shares fell nearly 2% in morning trade Monday.Earnings per share were 0.0303 yuan, compared with 0.0363 yuan in the prior-year period.Revenue rose 11% year on year to 191.3 million yuan, figures showed.

HKG:1449
Asia

Market Chatter: CSL, Resmed, Cochlear Lead Losses on ASX

CSL (ASX:CSL) led losses on the Australian bourse so far this year at AU$23.2 billion, while ResMed (ASX:RMD) and Cochlear (ASX:COH) followed with losses of AU$10.6 billion, the Australian Financial Review reported Monday, citing Global X ETFs.Negative performing companies on the S&P/ASX 200 index collectively wiped out over AU$217 billion, said Marc Jocum, senior product and investment strategist at Global X ETFs.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

ASX:COHASX:CSLASX:RMD